Potentiation of intrathecal DAMGO antinociception, but not gastrointestinal transit inhibition, by 5-hydroxytryptamine and norepinephrine uptake blockade.
Spinally administered mu opioid agonists produce potent antinociception and inhibition of gastrointestinal transit. Blockade of 5-hydroxytryptamine (5-HT) or norepinephrine (NE) uptake potentiates intrathecal (i.t.) DAMGO antinociception. To determine whether 5-HT and NE uptake blockade will also potentiate the gastrointestinal inhibition, mice were treated with zimelidine, desipramine or saline, followed by i.t. DAMGO and tested for tailflick antinociception or inhibition of gastrointestinal transit. DAMGO produced antinociception dose-dependently (ED50 = 4.6 ng). Zimelidine (10 mg/kg, s.c., 1 hr before DAMGO) produced a 6.2-fold leftward shift in the antinociceptive dose-response curve (ED50 = 0.73 ng). Desipramine produced a 5.3-fold shift (ED50 = 1.4 ng). DAMGO also produced a dose-dependent inhibition of gastrointestinal transit (ED50 = 117 ng). However, zimelidine or desipramine treatment did not affect DAMGO inhibition of gastrointestinal transit (ED50 = 80 ng.).
Paul
D
D
Department of Pharmacology, LSU Medical Center, New Orleans, LA 70112.
Hornby
P J
PJ
D000818:Animals; D003891:Desipramine / Q000008:administration & dosage*; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000008:administration & dosage*; D005769:Gastrointestinal Motility / Q000187:drug effects; D007278:Injections, Spinal; D008297:Male; D051379:Mice; D009638:Norepinephrine / Q000378:metabolism*; D010146:Pain / Q000188:drug therapy*; D017450:Receptors, Opioid, mu / Q000819:agonists; D012701:Serotonin / Q000378:metabolism*; D015031:Zimeldine / Q000008:administration & dosage*
D004745:Enkephalins; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D012701:Serotonin; D015031:Zimeldine; D003891:Desipramine; D009638:Norepinephrine